GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » Research & Development

Anterogen Co (XKRX:065660) Research & Development : ₩5,258 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Anterogen Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Anterogen Co's Research & Development for the three months ended in Mar. 2024 was ₩896 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ₩5,258 Mil.


Anterogen Co Research & Development Historical Data

The historical data trend for Anterogen Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anterogen Co Research & Development Chart

Anterogen Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,532.90 4,006.69 4,194.43 4,658.23 5,383.56

Anterogen Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,021.48 2,047.42 1,275.79 1,038.86 896.13

Anterogen Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩5,258 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anterogen Co  (XKRX:065660) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Anterogen Co Research & Development Related Terms

Thank you for viewing the detailed overview of Anterogen Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Anterogen Co (XKRX:065660) Business Description

Traded in Other Exchanges
N/A
Address
Namsung Plaza, Gasan-dong, 405, 130, Digital-ro, Geumcheon-gu, Seoul, KOR, 08589
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Anterogen Co (XKRX:065660) Headlines

No Headlines